NLRP3-IN-76 is an orally active NLRP3 inhibitor that suppresses the production of NO and reduces the mRNA levels of pro-inflammatory cytokines (iNOS, IL-6, IL-1beta, and TNFalpha). It exerts anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and the NF-kappaB signaling pathway. Furthermore, NLRP3-IN-76 can ameliorate DSS-induced colitis and is applicable for studying inflammatory bowel disease (IBD).
